Al Mayadeen English

  • Ar
  • Es
  • x
Al Mayadeen English

Slogan

  • News
    • Politics
    • Economy
    • Sports
    • Arts&Culture
    • Health
    • Miscellaneous
    • Technology
    • Environment
  • Articles
    • Opinion
    • Analysis
    • Blog
    • Features
  • Videos
    • NewsFeed
    • Video Features
    • Explainers
    • TV
    • Digital Series
  • Infographs
  • In Pictures
  • • LIVE
News
  • Politics
  • Economy
  • Sports
  • Arts&Culture
  • Health
  • Miscellaneous
  • Technology
  • Environment
Articles
  • Opinion
  • Analysis
  • Blog
  • Features
Videos
  • NewsFeed
  • Video Features
  • Explainers
  • TV
  • Digital Series
Infographs
In Pictures
  • Africa
  • Asia
  • Asia-Pacific
  • Europe
  • Latin America
  • MENA
  • Palestine
  • US & Canada
BREAKING
Israeli media platform: The Degel HaTorah party, which has four members in the Knesset, announces its withdrawal from Netanyahu's cabinet.
Local Syrian sources: The raids targeted the road between the village of Al-Mazra'a and the city of Sweida, where forces and factions affiliated with the Syrian Ministry of Defense are advancing.
Local Syrian sources: New raids carried out by Israeli warplanes targeted vehicles and gatherings of military factions affiliated with the new Syrian Ministry of Defense.
Local Syrian sources: Israeli raids target, for the third time, gatherings of Syrian Defense Forces military factions in the southern countryside of Sweida.
The Ministry of Health in Gaza: Gaza Strip hospitals received 120 martyrs and 557 wounded in the past 24 hours.
The Israeli Walla! website: We are running out of stockpiles, our forces are exhausted, and the lives of the captives are in danger. It is time for a ceasefire deal in Gaza.
Several wounded in an Israeli bombardment of a tent in al-Mawasi, south of Khan Younis in the Gaza Strip.
Israeli media: Three wounded, three killed in an ongoing operation in the Gaza Strip.
Al Mayadeen's correspondent in southern Lebanon: Israeli artillery shelling targets the outskirts of the town of Shebaa
Al-Qassam Brigades: The targeting took place at the intersection of 'Street 5' with the western line north of Khan Younis

Alzheimer's drug approval optimistic amid promising results

  • By Al Mayadeen English
  • Source: Agencies
  • 17 Jul 2023 23:44
3 Min Read

Following clinical trial results, another Alzheimer's drug proven to slow cognitive decline is one step closer to US approval.

  • x
  • A sign for Eli Lilly & Co. outside their headquarters in Indianapolis on April 26, 2017. New research shows another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening. (AP)
    A sign for Eli Lilly & Co. outside their headquarters in Indianapolis on April 26, 2017. (AP)

As a consequence of clinical trial findings that were published in a reputable publication on Monday, a second Alzheimer's medication that has been shown to reduce cognitive loss moved one step closer to US approval.

After years of little advancement in the field, many experts have welcomed the results as significant advances. However, others have advised caution, characterizing the advantages as limited while highlighting the high prices and risks of life-threatening side effects.

A study published in the Journal of the American Medical Association (JAMA) found that the medicine donanemab reduced the progression of symptoms over an 18-month period by 35% in comparison to placebo in approximately 1,200 persons with early-stage Alzheimer's disease.

Read: 19-year-old Chinese man becomes youngest patient with Alzheimer's

Results from cognitive tests and participants' capacity to complete daily tasks were used to gauge this. Drugmaker Eli Lilly, which said it anticipates regulatory action in the United States by the end of the year, produces the medication, which is administered intravenously every four weeks.

The release of the new research coincides with the US Food and Drug Administration's decision to allow Leqembi, a medication created by Biogen and Eisai, to be covered by Medicare, the nation's sponsored insurance program for the elderly.

Both function by focusing on the protein amyloid beta, which damages cognition when it builds up in the brain.

Related News

UN report reveals cocaine in upward trend, meth market expands

288 people arrested by Europol in massive dark web crackdown

"These first-generation drugs are by no means perfect, but represent an important breakthrough," interim director of the UK Dementia Research Institute, Giles Hardingham, said in a statement.

However, he added that it was equally crucial to understand that Alzheimer's is a complex illness and that amyloid beta was merely one factor in its development.

However, Eric Widera of the University of California, San Francisco, and colleagues argued that it was too early to conclude that the new medications would be helpful in the long run. Such opinions appeared in an editorial that was published alongside the new results in JAMA.

They claimed that Donanemab and Leqembi, also known as lecanemab, do not treat Alzheimer's disease but rather cause "slightly less worsening" in patients.

"The modest benefits would likely not be questioned by patients, clinicians, or payers if amyloid antibodies were low risk, inexpensive, and simple to administer. However, they are none of these," the authors wrote.

Patients will still be responsible for thousands of dollars in out-of-pocket expenses even after Medicare covers 80% of the expenditures.

Additionally, three deaths that were most likely brought on by the therapies that cause brain bleeds occurred in the investigations of donanemab and Leqembi.

Given that anti-amyloid therapies also speed up brain atrophy, research indicates that it will be critical to gather more information as the treatments enter the real world to determine whether they continue to decrease cognitive decline past 18 months or if they have the opposite effect.

Additionally, since 96% of the patients in the donanemab trial were white despite the fact that Black and Latino persons had a much greater prevalence of Alzheimer's, this means that important demographics still remain understudied.

  • Eli Lilly
  • Alzheimer's Disease
  • Drug

Most Read

Hezbollah SG reveals war details on Al Mayadeen for the first time

Hezbollah SG reveals war details on Al Mayadeen for the first time

  • Politics
  • 8 Jul 2025
Major ambush in Gaza kills 6 Israeli troops, injures dozens

Major ambush in Gaza kills 5 Israeli troops, injures 14

  • Politics
  • 8 Jul 2025
Israeli soldiers are seen in Beit Hanoun ahead of an operation by the al-Qassam Brigades, undated (Al-Qassam Brigades Military Media)

'Israel' on blast as media exposes report discrepancies in Gaza ambush

  • Palestine
  • 8 Jul 2025
Yemen Navy sinks ETERNITY C ship, shares footage of operation

Yemen Navy sinks ETERNITY C ship, shares footage of operation

  • Politics
  • 9 Jul 2025

Coverage

All
The Ummah's Martyrs

Read Next

All
Al Mayadeen: UN Palestine Inquiry members reportedly resigned
Politics

Al Mayadeen: UN Palestine Inquiry members reportedly resigned

Rutte, Trump
US & Canada

Trump threatens 100% secondary tariffs on Russia, sets deadline

Syrian government soldiers on a motorcycle pass by a burning tank on the outskirts of Sweida city, where clashes erupted between the Druze community and Bedouine clans, in southern Syria, Monday, July 14, 2025 (AP)
Politics

Israeli airstrikes target Syrian military factions near Sweida

Lebanon, US, disarmament
MENA

US pressure on Lebanon grows over Resistance disarmament plan

Al Mayadeen English

Al Mayadeen is an Arab Independent Media Satellite Channel.

All Rights Reserved

  • x
  • Privacy Policy
  • About Us
  • Contact Us
  • Authors
Android
iOS